$MCRB Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Seres Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Seres Therapeutics, Inc.. Get notifications about new insider transactions in Seres Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 2021 | MCRB | Seres Therapeutics ... | Nutritional Health LTP Fund Ge ... | 10% Owner | Sell | J | 0.00 | 295,171 | 0 | 2,962,963 | 3.3 M to 3 M (-9.06 %) |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Option Exercise | A | 26.34 | 100,000 | 2,634,000 | 100,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Option Exercise | A | 26.34 | 24,000 | 632,160 | 24,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Option Exercise | A | 0.00 | 12,000 | 0 | 12,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | von Moltke Lisa | See Remarks | Option Exercise | A | 26.34 | 110,000 | 2,897,400 | 110,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | Young Teresa L. | See Remarks | Option Exercise | A | 26.34 | 90,000 | 2,370,600 | 90,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | Shaff Eric D. | President, CEO | Option Exercise | A | 26.34 | 350,000 | 9,219,000 | 350,000 | |
| Feb 08 2021 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Option Exercise | A | 26.34 | 130,000 | 3,424,200 | 130,000 | |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Option Exercise | M | 6.01 | 27,562 | 165,648 | 45,938 | |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Option Exercise | M | 9.89 | 26,250 | 259,613 | 3,750 | |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Option Exercise | M | 0.71 | 26,000 | 18,460 | 0 | |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Sell | S | 28.34 | 9,841 | 278,894 | 0 | 9.8 K to 0 (-100.00 %) |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Sell | S | 27.56 | 26,265 | 723,863 | 9,841 | 36.1 K to 9.8 K (-72.74 %) |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Sell | S | 26.56 | 55,706 | 1,479,551 | 36,106 | 91.8 K to 36.1 K (-60.67 %) |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Buy | M | 6.01 | 27,562 | 165,648 | 91,812 | 64.3 K to 91.8 K (+42.90 %) |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Buy | M | 9.89 | 26,250 | 259,613 | 64,250 | 38 K to 64.3 K (+69.08 %) |
| Dec 03 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Buy | M | 0.71 | 26,000 | 18,460 | 38,000 | 12 K to 38 K (+216.67 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Berenson Stephen | Director | Buy | J | 0.00 | 3,589 | 0 | 3,589 | 0 to 3.6 K |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 43,154 | 0 | 0 | 43.2 K to 0 (-100.00 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 1,481,481 | 0 | 2,962,963 | 4.4 M to 3 M (-33.33 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 1,186,310 | 0 | 3,258,134 | 4.4 M to 3.3 M (-26.69 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 966,234 | 0 | 0 | 966.2 K to 0 (-100.00 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 642,180 | 0 | 1,283,282 | 1.9 M to 1.3 M (-33.35 %) |
| Nov 25 2020 | MCRB | Seres Therapeutics ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Sell | J | 0.00 | 3,587,820 | 0 | 4,434,600 | 8 M to 4.4 M (-44.72 %) |
| Oct 21 2020 | MCRB | Seres Therapeutics ... | Ege David S. | See Remarks | Option Exercise | A | 32.60 | 200,000 | 6,520,000 | 200,000 | |
| Jul 01 2020 | MCRB | Seres Therapeutics ... | Young Teresa L. | See Remarks | Option Exercise | A | 4.67 | 300,000 | 1,401,000 | 300,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Biondi Paul | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Berenson Stephen | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Graves Kurt | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Zausner Meryl | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Kender Richard N | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Dere Willard H | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Jun 22 2020 | MCRB | Seres Therapeutics ... | Behar Gregory | Director | Option Exercise | A | 4.40 | 30,000 | 132,000 | 30,000 | |
| Apr 24 2020 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Option Exercise | A | 3.74 | 18,596 | 69,549 | 18,596 | |
| Apr 07 2020 | MCRB | Seres Therapeutics ... | von Moltke Lisa | See Remarks | Option Exercise | A | 3.32 | 325,000 | 1,079,000 | 325,000 | |
| Mar 23 2020 | MCRB | Seres Therapeutics ... | Biondi Paul | Director | Option Exercise | A | 3.10 | 30,000 | 93,000 | 30,000 | |
| Jan 31 2020 | MCRB | Seres Therapeutics ... | Shaff Eric D. | President CFO | Option Exercise | A | 3.30 | 1,000,000 | 3,300,000 | 1,000,000 | |
| Jan 31 2020 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Option Exercise | A | 3.30 | 125,000 | 412,500 | 125,000 | |
| Jan 31 2020 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Option Exercise | A | 3.30 | 350,000 | 1,155,000 | 350,000 | |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CEO and President | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CEO and President | Buy | M | 0.00 | 20,000 | 0 | 32,842 | 12.8 K to 32.8 K (+155.74 %) |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Option Exercise | M | 0.00 | 25,000 | 0 | 0 | |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Buy | M | 0.00 | 25,000 | 0 | 41,054 | 16.1 K to 41.1 K (+155.72 %) |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Option Exercise | M | 0.00 | 7,500 | 0 | 0 | |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Henn Matthew R. | See Remarks | Buy | M | 0.00 | 7,500 | 0 | 12,000 | 4.5 K to 12 K (+166.67 %) |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Option Exercise | M | 0.00 | 12,500 | 0 | 0 | |
| Jan 28 2020 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Buy | M | 0.00 | 12,500 | 0 | 105,250 | 92.8 K to 105.3 K (+13.48 %) |
| Nov 25 2019 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Option Exercise | M | 0.00 | 12,000 | 0 | 0 | |
| Nov 25 2019 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Sell | S | 3.91 | 3,400 | 13,297 | 8,600 | 12 K to 8.6 K (-28.33 %) |
| Nov 25 2019 | MCRB | Seres Therapeutics ... | Chapman Marcus | See Remarks | Buy | M | 0.00 | 12,000 | 0 | 12,000 | 0 to 12 K |
| Aug 06 2019 | MCRB | Seres Therapeutics ... | Berenson Stephen | Director | Option Exercise | A | 2.44 | 30,000 | 73,200 | 30,000 | |
| Jun 20 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | P | 2.25 | 4,444,444 | 9,999,999 | 4,444,444 | 0 to 4.4 M |
| Jun 20 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Buy | P | 2.25 | 4,444,444 | 9,999,999 | 4,444,444 | 0 to 4.4 M |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Kim Lorence H. | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Pomerantz Roger | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Dere Willard H | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Behar Gregory | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Graves Kurt | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Kender Richard N | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Ausiello Dennis A | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | HORGAN KEVIN | Chief Medical Offic ... | Option Exercise | A | 6.01 | 30,000 | 180,300 | 30,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Option Exercise | M | 0.00 | 15,000 | 0 | 25,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Option Exercise | A | 6.01 | 84,800 | 509,648 | 84,800 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Sell | S | 5.75 | 5,471 | 31,478 | 16,054 | 21.5 K to 16.1 K (-25.42 %) |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | DesRosier Thomas | Chief Legal Officer ... | Buy | M | 0.00 | 15,000 | 0 | 21,525 | 6.5 K to 21.5 K (+229.89 %) |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Shaff Eric D. | See Remarks | Option Exercise | M | 0.00 | 12,000 | 0 | 20,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Shaff Eric D. | See Remarks | Option Exercise | A | 6.01 | 275,000 | 1,652,750 | 275,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Shaff Eric D. | See Remarks | Sell | S | 5.75 | 4,378 | 25,188 | 12,842 | 17.2 K to 12.8 K (-25.42 %) |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Shaff Eric D. | See Remarks | Buy | M | 0.00 | 12,000 | 0 | 17,220 | 5.2 K to 17.2 K (+229.89 %) |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Option Exercise | M | 0.00 | 7,500 | 0 | 12,500 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Option Exercise | A | 6.01 | 60,000 | 360,600 | 60,000 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Buy | M | 0.00 | 7,500 | 0 | 92,750 | 85.3 K to 92.8 K (+8.80 %) |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | COOK DAVID N | See Remarks | Option Exercise | M | 0.00 | 7,500 | 0 | 12,500 | |
| Jan 29 2019 | MCRB | Seres Therapeutics ... | COOK DAVID N | See Remarks | Buy | M | 0.00 | 7,500 | 0 | 147,435 | 139.9 K to 147.4 K (+5.36 %) |
| Dec 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
| Dec 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Buy | M | 0.00 | 10,000 | 0 | 85,250 | 75.3 K to 85.3 K (+13.29 %) |
| Dec 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Sell | S | 6.39 | 14,282 | 91,313 | 75,250 | 89.5 K to 75.3 K (-15.95 %) |
| Nov 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 8.26 | 14,279 | 117,912 | 89,532 | 103.8 K to 89.5 K (-13.75 %) |
| Oct 24 2018 | MCRB | Seres Therapeutics ... | HORGAN KEVIN | Chief Medical Offic ... | Option Exercise | A | 6.58 | 225,000 | 1,480,500 | 225,000 | |
| Oct 16 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 5.94 | 14,279 | 84,800 | 103,811 | 118.1 K to 103.8 K (-12.09 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 7.27 | 14,279 | 103,875 | 118,090 | 132.4 K to 118.1 K (-10.79 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 7.27 | 14,279 | 103,875 | 118,090 | 132.4 K to 118.1 K (-10.79 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 7.57 | 14,279 | 108,069 | 132,369 | 146.6 K to 132.4 K (-9.74 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 7.57 | 14,279 | 108,069 | 132,369 | 146.6 K to 132.4 K (-9.74 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 8.08 | 14,279 | 115,400 | 146,648 | 160.9 K to 146.6 K (-8.87 %) |
| Sep 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | See Remarks | Sell | S | 8.08 | 14,279 | 115,400 | 146,648 | 160.9 K to 146.6 K (-8.87 %) |
| Sep 11 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.00 | 1,810 | 16,291 | 213,976 | 215.8 K to 214 K (-0.84 %) |
| Sep 06 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.04 | 3,013 | 27,235 | 215,786 | 218.8 K to 215.8 K (-1.38 %) |
| Sep 06 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.12 | 9,505 | 86,714 | 218,799 | 228.3 K to 218.8 K (-4.16 %) |
| Sep 04 2018 | MCRB | Seres Therapeutics ... | Zausner Meryl | Director | Option Exercise | A | 8.47 | 30,000 | 254,100 | 30,000 | |
| Jul 18 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Sell | S | 8.10 | 14,279 | 115,726 | 160,927 | 175.2 K to 160.9 K (-8.15 %) |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 1,010 | 717 | 797,536 | |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.01 | 1,010 | 9,099 | 228,304 | 229.3 K to 228.3 K (-0.44 %) |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 1,010 | 717 | 229,314 | 228.3 K to 229.3 K (+0.44 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 5,989 | 4,252 | 798,546 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 10,981 | 7,797 | 804,535 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 15,366 | 10,910 | 815,516 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.05 | 5,989 | 54,208 | 228,304 | 234.3 K to 228.3 K (-2.56 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 5,989 | 4,252 | 234,293 | 228.3 K to 234.3 K (+2.62 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.14 | 10,981 | 100,351 | 228,304 | 239.3 K to 228.3 K (-4.59 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 10,981 | 7,797 | 239,285 | 228.3 K to 239.3 K (+4.81 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.14 | 15,366 | 140,507 | 228,304 | 243.7 K to 228.3 K (-6.31 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 15,366 | 10,910 | 243,670 | 228.3 K to 243.7 K (+6.73 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 4,496 | 3,192 | 830,882 | |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,560 | 15,308 | 835,378 | |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.10 | 4,496 | 40,915 | 228,304 | 232.8 K to 228.3 K (-1.93 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 4,496 | 3,192 | 232,800 | 228.3 K to 232.8 K (+1.97 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.15 | 21,560 | 197,375 | 228,304 | 249.9 K to 228.3 K (-8.63 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,560 | 15,308 | 249,864 | 228.3 K to 249.9 K (+9.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Dere Willard H | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Dere Willard H | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Kender Richard N | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Kender Richard N | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,991 | 12,064 | 856,938 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,991 | 12,064 | 856,938 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,224 | 15,069 | 873,929 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,224 | 15,069 | 873,929 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,288 | 11,564 | 895,153 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,288 | 11,564 | 895,153 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.03 | 16,991 | 153,408 | 228,304 | 245.3 K to 228.3 K (-6.93 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.03 | 16,991 | 153,408 | 228,304 | 245.3 K to 228.3 K (-6.93 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,991 | 12,064 | 245,295 | 228.3 K to 245.3 K (+7.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,991 | 12,064 | 245,295 | 228.3 K to 245.3 K (+7.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.19 | 21,224 | 195,133 | 228,304 | 249.5 K to 228.3 K (-8.51 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.19 | 21,224 | 195,133 | 228,304 | 249.5 K to 228.3 K (-8.51 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,224 | 15,069 | 249,528 | 228.3 K to 249.5 K (+9.30 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,224 | 15,069 | 249,528 | 228.3 K to 249.5 K (+9.30 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.21 | 26,752 | 246,504 | 228,304 | 255.1 K to 228.3 K (-10.49 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.21 | 26,752 | 246,504 | 228,304 | 255.1 K to 228.3 K (-10.49 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,288 | 11,564 | 255,056 | 238.8 K to 255.1 K (+6.82 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,288 | 11,564 | 255,056 | 238.8 K to 255.1 K (+6.82 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Kim Lorence H. | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Kim Lorence H. | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | AFEYAN NOUBAR | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Behar Gregory | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Behar Gregory | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Ausiello Dennis A | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Ausiello Dennis A | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Graves Kurt | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Graves Kurt | Director | Option Exercise | A | 9.09 | 15,000 | 136,350 | 15,000 | |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.36 | 40,057 | 374,761 | 238,768 | 278.8 K to 238.8 K (-14.37 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.06 | 18,987 | 172,094 | 278,825 | 297.8 K to 278.8 K (-6.38 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.33 | 26,492 | 247,051 | 297,812 | 324.3 K to 297.8 K (-8.17 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.36 | 40,057 | 374,761 | 238,768 | 278.8 K to 238.8 K (-14.37 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.06 | 18,987 | 172,094 | 278,825 | 297.8 K to 278.8 K (-6.38 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.33 | 26,492 | 247,051 | 297,812 | 324.3 K to 297.8 K (-8.17 %) |
| Jun 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Option Exercise | M | 0.00 | 5,000 | 0 | 10,000 | |
| Jun 19 2018 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Buy | M | 0.00 | 5,000 | 0 | 175,206 | 170.2 K to 175.2 K (+2.94 %) |